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Differentiating acute Q fever from infections caused by 
other pathogens is essential. We conducted a retrospec-
tive case–control study to evaluate differences in clinical 
signs, symptoms, and outcomes for 82 patients with acute 
Q fever and 52 control patients who had pneumonia, fever 
and lower respiratory tract symptoms, or fever and hepati-
tis, but had negative serologic results for Q fever. Patients 
with acute Q fever were younger and had higher C-reactive 
protein levels but lower leukocyte counts. However, a large 
overlap was found. In patients with an indication for prophy-
laxis, chronic Q fever did not develop after patients received 
prophylaxis but did develop in 50% of patients who did not 
receive prophylaxis. Differentiating acute Q fever from other 
respiratory infections, fever, or hepatitis is not possible with-
out serologic testing or PCR. If risk factors for chronic Q 
fever are present, prophylactic treatment is advised.
Q fever is a zoonosis caused by the bacterium Coxiella burnetii. During 2007–2010, the southern part of the 
Netherlands had the largest outbreak of Q fever ever re-
ported (1,2). Infection with C. burnetii is symptomatic in 
≈40% of all patients (3). Clinical signs range from a mild 
influenza-like illness to pneumonia or a hepatitis-like syn-
drome and can differ by region (4,5). After initial infection, 
chronic Q fever will develop in 1%–5% of patients (1,3). 
Furthermore, long-lasting fatigue will develop in ≈20% of 
all patients with symptomatic acute Q fever (6–8) without 
development of chronic Q fever (9).
Treatment for acute infection decreases the duration of 
fever, increases recovery from pneumonia (10), and might 
lead to a lower percentage of patients in whom chronic Q 
fever will develop (10–13). In addition, several reports in-
dicate that, in acute Q fever patients at risk for development 
of chronic Q fever, prophylactic treatment might prevent 
persistent infection (12,14). Therefore, recognizing Q fever 
in an early stage is a useful strategy.
The only available data on symptoms of acute Q fe-
ver in the Netherlands were obtained from a retrospective 
study that collected data several months after onset of dis-
ease by sending questionnaires to patients with acute Q fe-
ver (15). However, this method for obtaining data is limited 
by a high risk for recall bias. To help physicians differenti-
ate acute Q fever from other diseases, a clear description of 
signs and symptoms compatible with C. burnetii infection 
is desirable.
The purpose of this case–control study was to evaluate 
differences in clinical signs and symptoms between patients 
with acute Q fever referred to a hospital and a control group 
of patients with signs and symptoms that led to addition of 
Q fever in the differential diagnosis. Furthermore, outcome 
of patients hospitalized with acute Q fever were evaluated, 
and the effect of prophylactic treatment for those patients 
with an indication to prevent development of chronic Q fe-
ver was analyzed.
Materials and Methods
Patients
The study group consisted of adult patients who came to the 
Radboud university medical center or Canisius Wilhelmi-
na Hospital in Nijmegen, the Netherlands, during January 
2007–March 2011 with pneumonia, fever and lower respi-
ratory tract symptoms, or fever and hepatitis, and who were 
given a diagnosis of acute Q fever. Symptoms had to be 
present for <3 weeks before presentation. Exclusion criteria 
were chronic Q fever and a known previous acute Q fever 
episode. The same clinical criteria were used for the con-
trol group, but Q fever serologic results and, if available, 
PCR results had to remain negative. A standardized case 
report form was completed for every patient. According 
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to national law, this study was exempt from approval by an 
ethics committee because of the retrospective characteris-
tics of the study and the anonymous storage of data.
PCR and Serologic Analysis
During January 2007–March 2011, several laboratory 
techniques were used to diagnose acute Q fever. Because 
both hospitals collaborate extensively, the same microbio-
logical laboratory techniques were used in both hospitals. 
The PCR used to detect DNA of C. burnetii in serum was 
an in-house, real-time PCR directed against insertion se-
quence IS1111a.
Serologic analysis was performed for blood samples 
by using the Coxiella burnetii (Q Fever) IgM ELISA (Pan-
Bio Pty Ltd., Windsor, Queensland, Australia), which de-
tects IgM against phase II antigens and has a cutoff index 
of 1.1; a complement fixation assay (CFA) (Virion-Serion, 
Würzburg, Germany), which detects C. burnetii phase II 
antigens and shows a positive result if the titer is >1:10; 
and a Q fever immunofluorescent assay (IFA) for IgG and 
IgM (Focus Diagnostics Inc., Cypress, CA, USA), which 
detects IgM and IgG against phase I and phase II antigens 
and shows a positive result if the titer is >1:16.
Definition of Acute Q Fever
On the basis of the algorithm published by the Dutch work-
ing group on diagnostics of acute Q fever (16), the follow-
ing definition of acute Q fever was used for all included 
patients: pneumonia, lower respiratory tract symptoms and 
fever, or hepatitis-like symptoms and fever, all <3 weeks 
before presentation; and 1) a positive serum PCR result 
<21 days of onset of disease; or 2) a negative serum PCR 
result, but a positive ELISA result for IgM against phase 
II antigens of C. burnetii and a positive CFA result for im-
munoglobulins against C. burnetii; or 3) a negative serum 
PCR result but a positive ELISA result and a positive IFA 
result for IgM and IgG against phase I and phase II antigens 
of C. burnetii; or 4) two serum samples tested by CFA or 
IFA during an interval of >2 weeks that showed serocon-
version or a 4-fold increase in titer. 
A blood sample for Q fever serologic analysis obtained 
>2 weeks after the first day of illness was required because 
it was not possible to rule out acute Q fever if serologic 
samples are taken only at an earlier point, even if PCR re-
sults were negative during that period (16). Patients were 
selected only if an appropriate diagnostic procedure for Q 
fever was performed.
Treatment
Adequate treatment for acute Q fever was defined as anti-
microbial drug therapy with doxycycline (200 mg/d), moxi-
floxacin (400 mg 1×/d), or ciprofloxacin (500 mg 2×/d) for 
>14 days (17,18). Indications for prophylactic treatment to 
prevent development of chronic Q fever were patients who 
met the criteria for endocarditis prophylaxis according to 
the international guidelines of the American Heart Associa-
tion (19); patients with a structural aortic valve defect or 
mitral valve defect (12); patients with a known aneurysm of 
the aorta or other large vessels; and patients with a vascular 
prosthesis. Adequate prophylactic treatment was defined as 
doxycycline (200 mg/d) and hydroxychloroquine (200 mg 
3×/d) for >6 months.
Statistical Methods
All data were analyzed by using SPSS version 20.0 (IBM, 
Armonk, NY, USA). For analysis of qualitative data, the 
Pearson’s χ2 test was used. To evaluate the effect of pro-
phylactic treatment, the Barnard exact test was used be-
cause this test is more powerful than the Fisher exact test 
for instances of smaller sample sizes (20). For quantitative 
data, the Student t-test was used. A p value <0.05 was con-
sidered significant.
Results
General Characteristics
A total of 82 patients with acute Q fever who fulfilled in-
clusion criteria for the study group and 52 patients who 
fulfilled criteria for the control group were included in the 
study (Table 1). Patients with acute Q fever were younger 
(mean ± SD age 52 ± 16 years vs. 59 ± 16 years; p = 0.03); 
had less often a history of lung disease (p = 0.001); and 
were immunocompromised less often (p = 0.002). Patients 
with acute Q fever had more history of smoking (p = 0.01) 
and a higher frequency of a sore throat (p = 0.008) (Table 
2). Production of sputum was reported less frequently by 
patients with acute Q fever (p = 0.049).
Physical Examination
Of patients with acute Q fever, 18% had shortness of breath 
(Table 3) compared with 44% in the control group (p = 
0.03). A total of 4% of patients with acute Q fever had 
rhonchi at pulmonary examination compared with 22% in 
the control group (p = 0.005). Oxygen saturation was sig-
nificantly higher in patients with acute Q fever (p = 0.02).
Laboratory Values
Patients with acute Q fever had a higher levels of C-reac-
tive protein (mean 167 mg/L vs. 117 mg/L; p = 0.02) (Ta-
ble 4) and lower leukocyte counts (mean 9.0 × 109 cells/L 
vs. 11.5 × 109 cells/L; p = 0.006). Leukocyte counts re-
mained significantly lower in the first 3 days after pre-
sentation (p = 0.006–0.043). At admission to the hospi-
tal, no differences were found between the groups for 
levels of alkaline phosphatase and γ-glutamyl transpep-
tidase. However, from day 1 onward, levels of alkaline 
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phosphatase and γ-glutamyl transpeptidase were signifi-
cantly higher in patients with acute Q fever (p = 0.01–
0.047 and p = 0.007–0.05, respectively).
PCR and Serologic Analysis
Serum PCR for DNA of C. burnetii was performed for 41 
patients in the study group (Table 5). Blood samples were 
obtained at day 8 ± 7 (mean ± SD) of illness. The sensitiv-
ity of this PCR was 56%. For 4 patients, a second blood 
sample was obtained at day 12 ± 5 of illness. The sensitiv-
ity of this PCR was 25%.
ELISA was performed on samples from 33 patients 
with acute Q fever and 18 patients in the control group. 
Blood samples were obtained from the study group at day 
10 ± 8 of illness and from the control group at day 7 ± 6 of 
illness. Sensitivity of this ELISA was 61%.
CFA, which was performed for 81 patients in the study 
group at day 9 ± 19 of illness and for 52 patients in the 
control group at day 8 ± 6 of illness, showed a sensitivity 
of 22% (Table 5). A total of 57 patients were hospitalized, 
of whom 36 were given a diagnosis of acute Q fever during 
their hospitalization.
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Table 1. Characteristics for patients with acute Q fever and control group with negative serologic results for Q fever, the Netherlands* 
Characteristic Study group Control group p value 
No. patients 82 52 NS† 
Male sex, no. (%) 53 (65) 38 (73) NS‡ 
Mean  SD age, y (range) 52  16 (23–91) 59  16 (19–85) 0.027† 
Mean no. days between first day of sickness and presentation 5.5 5.4 NS† 
History of lung disease 8/78 (10) 18/51 (35) 0.001‡ 
Immunocompromised§ 5/81 (6) 13/51 (25)  0.002‡ 
Valvular dysfunction 8/82 (10) 3/52 (6) NS‡ 
Valve prosthesis 3/82 (4) 0/52 (0) NS‡ 
Aneurysm 2/82 (2) 3/52 (6) NS‡ 
Vascular prosthesis 3/82 (4) 3/52 (6) NS‡ 
Liver disease 1/82 (1) 1/52 (2) NS‡ 
Malignancy 2/82 (2) 9/52 (17) 0.002‡ 
Diabetes 9/82 (11) 7/52 (13) NS‡ 
Contact with cattle 29/47 (62) 8/20 (40) NS‡ 
History of smoking 58/74 (78) 25/44 (57) 0.013‡ 
Alcohol use 17/44 (39) 12/27 (44) NS‡ 
Illicit drugs 4/35 (11) 0/18 (0) NS‡ 
Proton pump inhibitors¶ 13/82 (16) 22/52 (42) 0.001‡ 
Corticosteroids¶ 5/82 (6) 10/51 (20) 0.017‡ 
*Values are no. positive/no. tested (%) unless otherwise indicated. NS, not significant. 
†By Student t-test. 
‡By 2 test. 
§Also includes patients using corticosteroids. 
¶Only medications that differed significantly between groups is shown. 
 
 
 
 
Table 2. Signs and symptoms for patients with acute Q fever and control group with negative serologic results for Q fever,  
the Netherlands* 
Characteristic 
Study group, n = 82, no. 
positive/no. tested (%) 
Control group, n = 52, no. 
positive/no. tested (%) p value† 
Fever 64/75 (85) 37/49 (76) NS 
Chills 31/42 (74) 16/28 (57) NS 
Myalgia 22/24 (92) 11/14 (79) NS 
Night sweats 12/19 (63) 9/17 (53) NS 
Weight loss 11/26 (42) 7/14 (50) NS 
Chest pain 11/55 (20) 13/38 (34) NS 
Dyspnea 37/65 (57) 31/43 (72) NS 
Rhinorrhea 1/12 (8) 7/14 (50) NS 
Sore throat 12/22 (55) 1/12 (8) 0.008 
Cough 49/76 (64) 38/48 (79) NS 
Sputum production 18/73 (25) 20/48 (42) 0.049 
Nausea 14/48 (29) 12/37 (32) NS 
Vomiting 17/47 (36) 10/39 (26) NS 
Abdominal pain 9/51 (18) 6/33 (18) NS 
Diarrhea 9/50 (18) 4/36 (11) NS 
Headache 38/54 (70) 21/27 (78) NS 
Weakness 9/21 (43) 1/9 (11) NS 
Painful joints 7/20 (35) 2/16 (13) NS 
Arthritis 0/17 (0) 1/16 (6) NS 
*NS, not significant. 
†By 2 test. 
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Imaging Studies
A total of 78% of chest radiographs for patients with acute 
Q fever showed signs of pneumonia. A total of 54% of 
chest radiographs for patients in the control group showed 
signs of pneumonia (p = 0.003) (Table 5).
Treatment
Treatment was started before a diagnosis was made. Signif-
icantly more patients with acute Q fever started treatment 
with doxycycline than patients in the control group (35% 
vs. 15%; p = 0.001) (Table 6). For 8 patients in the study 
group, the duration of antimicrobial drug treatment was un-
known. Of the remaining 74 patients with acute Q fever, 34 
(46%) patients were given adequate treatment. The mean 
± SD follow-up time for patients given adequate treatment 
was 11.7 ± 5 months compared with 13.3 ± 9 months for 
patients given inadequate treatment.
Outcomes
Hospitalization (70% vs. 94%; p = 0.001), admission to an 
intensive care unit (4% vs. 18%; p = 0.002), and need for 
respiratory support (2% vs. 16%; p = 0.001) were less com-
mon for the study group than for the control group (Table 
7). Also, duration of hospital stay was shorter for patients 
with acute Q fever (9 ± 7 days vs. 17 ± 15 days; p = 0.001). 
Accurate follow-up data were available for 59 of 82 pa-
tients with acute Q fever who had a mean ± SD follow-
up of 12.8 ± 8.2 months. Chronic Q fever developed in 6 
(10%) patients in the Q fever group.
Sixteen patients with acute Q fever met the criteria for 
prophylactic treatment to prevent development of chronic Q 
fever (Table 8). Indications were valvular dysfunction (n = 
8); cardiac valve prosthesis (n = 3); aneurysm (n = 1); vas-
cular prosthesis (n = 3, of whom 1 patient also had a cardiac 
valve prosthesis); and a new cardiac murmur (n = 2). Eight 
(50%) of these patients received prophylactic treatment. 
Proper follow-up data for development of chronic Q fever 
were available for 14 patients with an indication for prophy-
laxis. Chronic Q fever did not develop in any of the 8 pa-
tients who received prophylaxis. The other 6 patients with an 
indication for prophylaxis for whom follow-up serum sam-
ples were available did not receive prophylaxis because the 
indication for prophylaxis was not recognized by the treating 
physician. Chronic Q fever developed in 3 (50%) of these 
6 patients (p = 0.02). In the group without an indication for 
prophylaxis, chronic Q fever developed in 3 (6%) patients. 
Six (11%) of 56 patients in the study group for whom these 
data were available reported long-lasting fatigue.
The mortality rate during a 12-month follow-up period 
was 6% for the study group compared with 19% for the 
control group (p = 0.02). None of the patients in the study 
group died during the episode of acute Q fever. Four pa-
tients in the study group died because of reasons unrelated 
to Q fever. One patient died of consequences of an infected 
vascular prosthesis caused by chronic Q fever, although 
adequate treatment was started after the diagnosis. In con-
trast, 2 patients in the control group died during initial hos-
pitalization, 1 of a Mycoplasma sp. infection and 1 of pneu-
monia without a known causative agent. Eight patients in 
the control group died during follow-up. One of them died 
of a non-Hodgkin lymphoma and 1 of consequences of an 
Aspergillus sp. infection. For the other 6 patients who died, 
no detailed information was available.
A total of 49 control patients were given a diagnosis of 
pneumonia; for 38 of these patients, no causative agent was 
found. For the remaining 11 patients, causative agents were 
Pneumocystis jiroveci, Moraxella catarrhalis, Legionnel-
la pneumophila, Chlamydia sp., Haemophilus influenzae 
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Table 3. Physical examination results for patients with acute Q fever and control group with negative serologic results for Q fever,  
the Netherlands* 
Characteristic Study group, n = 82 Control group, n = 52 p value 
Dyspnea 13/73 (18) 18/41 (44) 0.03† 
Abnormal heart sounds 1/80 (1) 0/51 (0) NS† 
Cardiac murmur 11/80 (14) 4/50 (8) NS† 
Decreased breath sounds 6/78 (8) 7/46 (15) NS† 
Bronchial breath sounds 9/64 (14) 5/37 (14) NS† 
Crackles 36/76 (47) 19/43 (44) NS† 
Rhonchi 3/68 (4) 9/41 (22) 0.005† 
Palpable liver 1/69 (1) 1/39 (3) NS† 
Palpable spleen 0/68 (0) 0/36 (0) NS† 
Exanthema 2/9 (22) 0/6 (0) NS† 
Lymphadenopathy 2/27 (7) 2/21 (10) NS† 
Temperature, C (no. patients) 38.4 (67) 38.3 (48) NS‡ 
Heart rate, beats/min (no, patients) 93 (73) 91 (50) NS‡ 
Systolic blood pressure, mm Hg, (no. patients) 134 (73) 138 (49) NS‡ 
Respiratory rate, breaths/ min (no. patients) 25 (24) 25 (21) NS‡ 
Saturation, % oxygenation (no. patients)§ 97 (57) 95 (34) 0.022‡ 
*Values are no positive/no. tested (%) unless otherwise indicated. NS, not significant. 
†By 2 test. 
‡By Student t-test. 
§Saturation without oxygen. 
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(2 patients), Mycoplasma sp. (3 patients), influenza vi-
rus and Mycoplasma sp., and Staphylococcus aureus and 
Streptococcus pneumonia. The remaining 3 patients were 
given diagnoses of acute myeloid leukemia, non-Hodgkin 
lymphoma, and restrictive pericarditis.
Discussion
This retrospective case–control study evaluated differences 
in clinical signs and symptoms between patients with acute 
Q fever referred to a hospital and a control group. Because 
patients in the control group had Q fever included in the 
differential diagnosis, a selection bias is possible. How-
ever, differences were found between the 2 groups. In ad-
dition, because of the Q fever outbreak during that time, C. 
burnetii was considered a possible etiologic agent in many 
patients who came to a hospital. The higher number of pa-
tients in the study group can be explained by strict imple-
mentation of inclusion criteria for the control group.
Consistent with findings of earlier studies (1,21), we 
found that patients with acute Q fever more often had a his-
tory of smoking. However, a history of lung disease was 
found less often. A lower mean age in the study group than 
in the control group might explain this finding. Previous 
studies suggest typical signs and symptoms of acute Q fever: 
fever, headache, and cough (1,3,22). However, no difference 
was observed in the occurrence of fever. It has been postu-
lated that headache is rather specific for acute Q fever (5,23). 
However, in our study, headache was less common in pa-
tients with acute Q fever than in the control group. Although 
cough was a relatively common sign in both groups, sputum 
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Table 4. Laboratory values for patients with acute Q fever and control group with negative serologic results for Q fever,  
the Netherlands* 
Laboratory value Day† 
Study group, n = 82 Control group, n = 52 
p value‡ Mean No. tested Mean No. tested 
Hemoglobin, mmol/L; reference range: men 8.1–10.7 
mmol/L, women 7.3–9.7 mmol/L 
0 8.3 77 8.0 51 NS 
1 7.4 28 7.3 34 NS 
2–3 7.7 27 7.0 29 0.036 
4–6 7.6 27 7.0 29 NS 
Leukocytes,  109 cells/L; reference range 3.5–11.0  109 
cells/L 
0 9.0 80 11.5 50 0.006 
1 8.5 40 10.8 28 0.043 
2–3 8.0 34 11.1 33 0.021 
4–6 10.9 28 9.2 31 NS 
Platelets,  109/L; reference range 20–350  109/L 0 239 78 208 50 NS 
1 242 23 178 29 0.038 
2–3 229 19 172 26 0.042 
4–6 298 24 208 27 0.011 
Total bilirubin, μmol/L; reference value <17 μmol/L 0 14 26 16 20 NS 
1 12 14 14 8 NS 
2–3 9 12 28 6 0.017 
4–6 8 12 9 6 NS 
AP, U/L; reference value <120 U/L 0 104 75 85 50 NS 
1 127 19 75 12 0.047 
2–3 126 26 66 12 0.010 
4–6 145 23 95 15 0.036 
ALT, U/L; reference value <45 U/L 0 45 76 37 49 NS 
1 64 22 58 16 NS 
2–3 66 30 40 13 0.050 
4–6 81 22 84 18 NS 
-GT, U/L; reference value: men <50 U/L, women <35 U/L 0 74 68 65 49 NS 
1 117 21 53 12 0.030 
2–3 106 27 42 9 0.007 
4–6 112 22 66 14 0.050 
CRP, mg/L; reference value <10 mg/L 0 167 79 117 50 0.015 
1 184 44 150 37 NS 
2–3 132 46 147 32 NS 
4–6 76 41 98 27 NS 
Urea, mmol/L; reference value 2.5–7 mmol/L 0 6.4 79 8.6 51 0.039 
1 6.4 33 7.9 35 NS 
2–3 5.4 38 8.7 35 0.014 
4–6 5.8 34 9.3 30 0.018 
Creatinine, μmol/L; reference value: men <110 μmol/L, 
women <90 μmol/L 
0 86 80 105 52 0.042 
1 84 38 103 38 NS 
2–3 79 37 103 37 NS 
4–6 81 36 136 31 NS 
*NS, not significant; AP, alkaline phosphatase; ALT, alanine aminotransferase; γ-GT, -glutamyl transpeptidase; CRP, C-reactive protein. 
†Day 0 is the day of coming to the hospital. 
‡By Student t-test. 
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production was reported less often in patients with acute Q 
fever. In addition, a sore throat was reported more often in 
the study group, which has not been previously reported.
A limitation of these results is the retrospective nature 
of the study because physicians probably did not include all 
signs and symptoms in patient charts. In general, patients 
with lung disease often use corticosteroids, which might ex-
plain why fewer patients in the study group were classified 
as immunocompromised. In contrast to medical and physi-
cal examination results, more patients with acute Q fever 
showed signs of an infiltrate on chest radiographs when they 
came to the hospital. Although acute Q fever usually is a 
relatively mild influenza-like disease, it has been reported 
that chest radiographs often shows signs of an infiltrate (24). 
Compared with our control group, fewer patients in the study 
group needed hospitalization, and duration of hospitalization 
was shorter. These findings might be explained by the lower 
mean age of patients with acute Q fever, assuming that they 
were in a more healthy condition. Furthermore, C. burnetii is 
known for its self-limiting character, in contrast to those of 
other pathogens found in the control group.
In the Netherlands, a Q fever hospitalization rate of 
50% in 2007 was registered, which stabilized at ≈20% in 
later years (25). This rate is higher than that previously 
reported (2%–5%) (5). However, large variations in hos-
pitalization rates for acute Q fever patients have been re-
ported (26). In this study, 70% of patients with acute Q 
fever were hospitalized. Most patients with acute Q fever 
are asymptomatic or have only a mild influenza-like illness. 
Thus, a selection bias caused by the study design is likely. 
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Table 5.  PCR and serologic results for patients in study group with acute Q fever and control group with negative serologic results for 
Q fever, the Netherlands* 
Characteristic Study group, n  = 82 Control group, n = 52 
Day of illness for 
study group, 
mean  SD 
Day of illness for 
control group, 
mean  SD Sensitivity, % 
PCR      
 First sample 23/41 0/15 8  7 8  7 56 
 Second sample 1/4 0/1 12  5 30  0 25 
ELISA 
 First sample 20/33 0/18 10  8 7  6 61 
 Second sample 15/18 0/2 20  11 25  8 83 
CFA 
 First sample 18/81 0/52 9  19 8  6 22 
 Second sample 27/34 0/28 18  9 20  12 79 
 Third sample 5/5 0/3 21  6 26  5 100 
 Culture 
 Blood† 0/42 (0) 0/40 (0) NA NA NA 
 Urine† 0/30 (0) 0/37 (0) NA NA NA 
 Sputum‡ 1/15 (7) 3/22 (14) NA NA NA 
Chest radiograph§ 62/79 (78) 28/52 (54) NA NA ¶ 
*Values are no. positive/no. tested (%) unless otherwise indicated. CFA, complement fixation assay; NA, not applicable. 
†Includes only results for first cultures obtained after coming to the hospital. 
‡Includes only results for first cultures obtained after coming to the hospital. In the study group, 1 patient was positive for parainfluenza virus. In the 
control group, 1 patient was positive for Moraxella catarrhalis, 1 patient was positive for Legionella pneumophila, and 1 patient was positive for 
Streptococcus pneumonia and Staphylococcus aureus. 
§Includes only first chest radiographs after coming to the hospital. Values are no. abnormal/no. tested (%).  
¶p = 0.003, by 2 test. 
 
 
 
 
Table 6. Initial treatment for patients with acute Q fever and control group with negative serologic results for Q fever, the Netherlands* 
Initial treatment 
Study group, n = 82, no. 
positive/no. tested (%) 
Control group, n = 52, no. 
positive/no. tested (%) p value† 
Doxycycline 29/82 (35) 8/52 (15) 0.001 
Moxifloxacin 5/82 (6) 2/52 (4) NS 
Ciprofloxacin 7/82 (9) 6/52 (12) NS 
Penicillin 7/82 (9) 1/52 (2) 0.049 
Amoxicillin 13/82 (16) 5/52 (10) NS 
Amoxicillin/clavulanic acid 3/82 (4) 4/52 (8) NS 
Piperacillin/tazobactam 1/82 (1) 5/52 (10) NS 
Cephalosporin 14/82 (17) 17/52 (33) NS 
Co-trimoxazole 0/82 (0) 1/52 (2) NS 
Flucloxacillin 2/82 (2) 0/52 (0) NS 
Clarithromycin 0/82 (0) 1/52 (2) NS 
No treatment 1/82 (1) 1/52 (2) NS 
Unknown 0/82 (0) 1/52 (2) NS 
Patients with adequate treatment‡ 34/74 (46) NA NA 
*NS, not significant; NA, not applicable. 
†By 2 test. 
‡Defined as use of doxycycline (200 mg/d), moxifloxacin (400 mg 1/d), or ciprofloxacin (500 mg 2/d) for >2 wk. 
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We found that 78% of patients in the study group had an ab-
normal result on a chest radiograph, which might indicate 
that only patients with severe symptoms were hospitalized.
Although C-reactive protein levels and leukocyte counts 
differed between the study group and the control group, this 
finding did not contribute to differentiation between C. bur-
netii and other pathogens at hospitalization because differ-
ences were small and showed much overlap. In addition, 
although leukocyte counts were usually within the reference 
range, patients with acute Q fever more often had a lower 
leukocyte count, which is consistent with results of other 
studies (3,4). In contrast to these studies, which found throm-
bocytopenia in patients with acute Q fever, we found slightly 
higher levels of platelets, all within the reference range, in 
the study group than in the control group. Increased levels 
of liver enzymes have been reported in patients with acute 
Q fever (3,5,22). However, we found no differences in these 
levels between both groups at hospitalization. Furthermore, 
creatinine levels were not increased, in contrast to results re-
ported in a previous study (3).
Although antimicrobial drug treatment was inade-
quate in an unexplainably high percentage of patients with 
acute Q fever, more patients in the study group than in the 
control group were initially treated with doxycycline, the 
treatment of choice for patients with acute Q fever. The 
choice of antimicrobial drug treatment in patients with 
community-acquired pneumonia (CAP) of unknown origin 
in the Netherlands depends on the Confusion, Urea nitro-
gen level in blood, Respiratory rate, Blood pressure, age 
>65 years (CURB-65) score (27). In addition, although 
CURB-65 scores could not be calculated for all patients, 
fewer patients in the study group were hospitalized, needed 
admission to an intensive care unit, and needed respiratory 
support, which suggests lower CURB-65 scores in the 
study group than in the control group.
Although changes were made in the national guidelines 
for treating CAP issued by the Dutch Working Party on An-
tibiotic Policy in 2011 (28), until 2011, doxycycline was 
the first choice for patients with a low CURB-65 score (29). 
In addition, more patients in the study group were given a 
diagnosis of having an infiltrate, which suggested that ini-
tial treatment in the study group was also aimed at atypical 
microorganisms. Presumably, patients in the control group 
were treated with broader spectrum antimicrobial drugs be-
cause of higher CURB-65 scores. Also, more patients in the 
control group were immunocompromised, which also could 
have influenced the choice of treatment.
Long-term prophylactic treatment with doxycycline and 
hydroxychloroquine has been suggested for patients with risk 
factors for development of chronic Q fever (12,14). Although 
controversy still exists (e.g., with regard to treatment duration 
and patient selection), prophylactic treatment of high-risk pa-
tients after an episode of acute Q fever can be beneficial and 
is widely advised (30–32). In our study, not all patients who 
had an indication according to our definition received pro-
phylaxis. Chronic Q fever developed in 3 of 6 patients who 
did not receive prophylaxis, in contrast to none of the patients 
who received prophylaxis, which is a difference that clearly 
supports findings of other studies in which prophylactic treat-
ment was suggested to prevent development of chronic Q 
fever in patients with risk factors for this disease (12,14). On 
the basis of these results, prophylactic treatment is advised if 
risk factors for developing chronic Q fever exist, but potential 
side effects must be taken into consideration (33).
For 48 of 67 patients without indication for prophylactic 
treatment, follow-up data were available on development of 
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Table 7. Outcome, follow-up, and prophylaxis for patients with acute Q fever and control group with negative serologic results for Q 
fever, the Netherlands* 
Characteristic Study group Control group p value 
Outcome    
 Hospitalized 57/82 (70) 49/52 (94) 0.001† 
 Need for ICU 2/57 (4) 9/49 (18) 0.002† 
 Need for respiratory support 1/57 (2) 8/49 (16) 0.001† 
 Mean  SD duration of hospitalization, d 9  7 17  15 0.001‡ 
 Mean  SD duration of time in ICU, d 5  1 14  10 0.266‡ 
Follow up 
 Development of chronic Q fever 6/59 (10) NA NA 
 Development of long-lasting fatigue§ 6/56 (11) NA NA 
 Death 5/82 (6) 10/52 (19) 0.019† 
 Q fever–related death 1/82 (1)¶ NA NA 
Indication for prophylaxis 16/82 (20) NA NA 
Development of chronic Q fever    
 Prophylactic treatment 0/8 (0) NA NA 
 No prophylactic treatment 3/6 (50) NA 0.018# 
*Values are no. positive/no. tested (%) unless otherwise indicated. ICU, intensive care unit; NA, not applicable. 
†By 2 test. 
‡By Student t-test. 
§Defined as persisting fatigue for >6 mo after acute Q fever in the absence of chronic Q fever. 
¶This patient died of consequences of an infected vascular prosthesis caused by chronic Q fever. 
#By unilateral Barnard exact test. 
 
Differentiation of Acute Q Fever from Other Infections
chronic Q fever. Chronic Q fever developed in 3 (6%) of 
these patients, which is slightly higher than expected (1,34). 
This finding might be explained by the fact that we included 
only patients who were referred to a hospital, and therefore 
selected patients most affected by C. burnetii infection. It 
is possible that more severely acute Q fever predisposes for 
development of chronic Q fever (13).
After having acute Q fever, patients often report long-
lasting fatigue, which frequently persists for >6 months. 
This symptom after acute Q fever has been designated Q 
fever fatigue syndrome. Our data suggest a prevalence of 
11%, which is lower than expected; other studies reported 
a prevalence of ≈20% worldwide and a higher prevalence 
in the Netherlands (6,35,36). The prevalence found in this 
study is presumably an underestimation because proper 
analysis was not performed for most patients.
Although we found some differences in clinical mani-
festations for patients with acute Q fever coming to a hospi-
tal compared with controls, considerable overlap between 
both groups hamper the use of these variables for clini-
cal differentiation. Differentiating C. burnetii from other 
pathogens is not possible without Q fever serologic analy-
sis and PCR in patients coming to a hospital. In disease-
endemic areas or in instances in which patients have risk 
factors for Q fever, suspicion should remain high, and the 
threshold for performing Q fever serologic analysis and 
PCR should remain low. Because only 46% of patients 
received adequate treatment acute Q fever in our study, 
treatment for acute Q fever should be improved. Further-
more, our findings underline the recommendation that pro-
phylactic treatment should be given to patients with risk 
factors for developing chronic Q fever. However, more 
studies are needed to develop uniform guidelines with re-
gard to optimal prophylactic treatment.
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